Indeed, transcripts for 29 out of 78 ATGs analyzed in this study were significantly altered in MS patients, with 14 genes downregulated (including ATG16L2, ATG9A, FAS, GAA, HGS, and RAB24) and 15 genes upregulated (including ULK1, PIK3R1, BLC2, FOXO1, HTT, and RGS19) (20), suggesting the involvement of ATG gene products in MS pathogenesis. This evidence concerns the gene ATG16L2 and myeloid sarcoma.